current stock price of jnj

Should you buy JNJ stock?

• EPS: US$1.93 (down from US$2.36 in 1Q 2021).
• Revenue: US$23.4b (up 5.0% from 1Q 2021).
• Net income: US$5.15b (down 17% from 1Q 2021).
• Profit margin: 22% (down from 28% in 1Q 2021). Higher expenses drove the decrease in the margin.

Is JNJ stock a buy or sell?

With a beta of 0.71, JNJ is the definition of a defensive stock. While strong share price growth should not be expected from this behemoth, when one also considers its status as a dividend aristocrat, as well as its sterling financial profile, JNJ stands out as a stock for risk averse investors. I rate JNJ as a BUY.

Why is JNJ stock falling?

Shares of Johnson & Johnson ( NYSE:JNJ) were sinking by 5.9% as of 3:31 p.m. EDT on Friday after the healthcare giant announced a recall of a single lot of its Johnson's Baby Powder. J&J stated in ...

When will JNJ stock split?

Johnson & Johnson (JNJ) will split into two public companies within the next 18 to 24 months. One will get its many consumer brands, while the other will get its pharmaceuticals, medical devices,...

See more

Is JNJ a buy right now?

Johnson & Johnson - Hold Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of B.

Is Johnson and Johnson stock worth buying?

Shares of J&J have an Investor's Business Daily Composite Rating of 95 out of a best-possible 99. The CR scores a stock's key growth metrics against all other stocks regardless of industry group. So in terms of key growth measures, JNJ stock outranks 95% of all stocks.

Is JNJ stock overpriced?

Because Johnson & Johnson is relatively overvalued, the long-term return of its stock is likely to be lower than its business growth, which averaged 3.6% over the past three years and is estimated to grow 4.55% annually over the next three to five years.

What is the target price for JNJ?

Stock Price TargetsHigh$215.00Median$187.00Low$165.00Average$187.29Current Price$173.68

Is Johnson and Johnson going out of business?

J&J itself isn't bankrupt—instead, it has split off a new unit essentially designed to go broke paying legal liabilities. It's part of a maneuver to deal with about 38,000 lawsuits, mostly filed by women who claim one of the company's oldest products, baby powder, causes ovarian cancer.

Is Johnson and Johnson a safe stock?

JNJ's strong financial fundamentals and its market position make it a highly secure option, with its diversified segments that result in a minimized risk exposure for the company.

Are Pfizer shares a good buy?

Over the past year, Pfizer (PFE -0.67%) has been one of the safer stocks to hold. Its 31% gain during that time eclipses the S&P 500 and its 9% loss. However, investors still aren't paying a huge premium for the stock as it trades at a relatively modest 12 times profits.

How will JNJ split affect stock?

If you stay invested in Johnson & Johnson through the split, the dividend payouts of both entities will be lower, but combined, the company said are expected to add up to the same amount investors are currently receiving.

Is PG a good stock to buy?

The consensus among 9 Wall Street analysts covering (NYSE: PG) stock is to Strong Buy PG stock.

How many times has Johnson and Johnson stock split?

According to our Johnson and Johnson stock split history records, Johnson and Johnson has had 6 splits.

What is the target price for Pfizer?

Stock Price TargetsHigh$75.00Median$55.00Low$49.00Average$56.85Current Price$52.30

Will PG stock go up?

The 21 analysts offering 12-month price forecasts for Procter & Gamble Co have a median target of 163.00, with a high estimate of 185.00 and a low estimate of 145.00. The median estimate represents a +12.41% increase from the last price of 145.00.

What are Johnson and Johnson products?

Where is Johnson and Johnson located?

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Ownership

Release

Sales

Risks

• 11 brokerages have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $146.00 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.

See more on marketbeat.com

Ratings

Reviews

Business